Table 1.

Characteristics of study population according to NUP98 gene fusion status

	All patient	NUP98+	NUP98-	P -value
Total	529	57	472
Protocol
AAML03P1, N (%)	55	5 (8.8%)	50 (10.6%)	0.670
AAML0531, N (%)	438	47 (82.4%)	391 (82.8%)	0.942
CCG-2961, N (%)	36	5 (8.8%)	31 (6.6%)	0.533
Gender				0.169
Male, N (%)	270	34 (59.6%)	236 (50%)
Female, N (%)	259	23 (40.4%)	236 (50%)
Median age at diagnosis (years, range)	8.9 (0-17.9)	9.8 (1.0-17.6)	8.5 (0-17.9)	0.293
Median WBC ×10^9/L (range)	40.5 (0.2–610)	53.5 (1.1-447.3)	39 (0.8–610)	0.160
FAB type, N (%)
M0	8	1 (1.8%)	7 (1.5%)	0.874
M1	36	8 (14.0%)	28 (5.9%)	0.028
M2	139	11 (19.3%)	128 (27.1%)	0.205
M4	143	14 (24.6%)	129 (27.3%)	0.657
M5	117	7 (12.3%)	110 (23.3%)	0.058
M6	4	4 (7.0%)	0 (0%)	< 0.001
M7	17	6 (10.5%)	11 (2.3%)	0.001
Treatment response
CR status at the end of course1, N (%)	412	34 (59.6%)	378 (80.1%)	< 0.001
CR status at the end of course2, N (%)	462	38 (66.7%)	424 (89.8%)	< 0.001
HSCT in CR1	51	11 (19.3%)	40 (8.5%)	0.009
FLT3/ITD
Positive, N (%)	55	26 (45.6%)	29 (6.1%)	< 0.001
Negative, N (%)	471	31 (54.4%)	440 (84.7%)	< 0.001
WT1 mutation
Positive, N (%)	32	15 (26.3%)	17 (3.6%)	< 0.001
Negative, N (%)	487	42 (73.7%)	445 (94.3%)	< 0.001
NPM1mutation
Positive, N (%)	8	3 (5.3%)	5 (1.1%)	0.014
Negative, N (%)	511	54 (94.7%)	457 (96.8%)	0.412
Cytogenetic status
Normal, N%	40	29 (50.9%)	11 (2.3%)	< 0.001
Abnormal, N%	479	22 (38.6%)	457 (96.8%)	< 0.001
Risk group
Low	242	4 (7.0%)	238 (50.4%)	< 0.001
Standard	238	30 (52.6%)	208 (44.1%)	0.402
high	41	19 (33.3%)	22 (4.7%)	< 0.001

Data for FAB classification, FLT3/ITD, NPM1, WT1 mutation, cytogenetic status and risk group were missing for some patients